The cost and cost-effectiveness of expedited partner therapy compared with standard partner referral for the treatment of chlamydia or gonorrhea

Sexually Transmitted Diseases

Volumn 38, Issue 11, 2011, Pages 1067-1073

  Gift, Thomas L ^a   Kissinger, Patricia ^b   Mohammed, Hamish ^c   Leichliter, Jami S ^a   Hogben, Matthew ^a   Golden, Matthew R ^d,e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b TULANE UNIVERSITY   (United States)

^c UNIVERSITY OF TRINIDAD AND TOBAGO   (Trinidad and Tobago)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Public Health Seattle King County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHLAMYDIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EXPEDITED PARTNER TREATMENT; FEMALE; GONORRHEA; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PELVIC INFLAMMATORY DISEASE; QUALITY ADJUSTED LIFE YEAR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE;

ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CONTACT TRACING; COST-BENEFIT ANALYSIS; FEMALE; GONORRHEA; HEALTH CARE COSTS; HUMANS; MALE; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; REFERRAL AND CONSULTATION; SEXUAL PARTNERS; SEXUALLY TRANSMITTED DISEASES; TREATMENT OUTCOME;

EID: 80054095405     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31822e9192     Document Type: Article

References (41)

1. Institute of Medicine. Prevention of STDs. In: Eng TR, Butler WT, eds. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press, 1997:118-174.
2. Golden MR, Hogben M, Handsfield HH, et al. Partner notification: Low coverage for gonorrhea, chlamydia, and HIV. Sex Transm Dis 2003; 30:490-496.
3. St. Lawrence JS, Montano DE, Kasprzyk D, et al. STD screening, testing, case reporting, and clinical and partner notification practices: A national survey of US physicians. Am J Public Health 2002; 92:1784-1788. (Pubitemid 35231140)
4. Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women. Sex Transm Dis 2003; 30:49-56. (Pubitemid 36071086)
5. Golden MR, Whittington WLH, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676-685. (Pubitemid 40239215)
6. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patientdelivered partner treatment for male urethritis: A randomized, controlled trial. Clin Infect Dis 2005; 41:623-629. (Pubitemid 41170350)
7. Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for Trichomonas vaginalis infection: A randomized controlled trial. Sex Transm Dis 2006; 33:445-450. (Pubitemid 43964755)
8. Cameron ST, Glasier A, Scott G, et al. Novel interventions to reduce re-infection in women with chlamydia: A randomized controlled trial. Hum Reprod 2009; 24:888-895.
9. Hodge JG, Pulver A, Hogben M, et al. Expedited partner therapy for sexually transmitted disease: Assessing the legal environment. Am J Public Health 2008; 98:238-243. (Pubitemid 351317558)
10. Centers for Disease Control and Prevention. Legal status of expedited partner therapy. Database on the Internet. Available at: http://www.cdc.gov/std/ ept/legal/default.htm. Accessed February 1, 2011.
11. US Office of Personnel Management. Salaries & wages, 2008. Database on the Internet. Available at: http://www.opm.gov/oca/08tables/indexGS.asp. Accessed March 19, 2010.
12. Yeh JM, Hook EW III, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003; 30:369-378. (Pubitemid 36605484)
13. Begley CE, McGill L, Smith PB. The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic. Sex Transm Dis 1989; 16:63-67. (Pubitemid 19154831)
14. Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis 2008; 35:S66-S75.
15. Medical Economics Company. Red Book. Montvale, NJ: Thomson Healthcare, 2008.
16. Owusu-Edusei K, Gift TL, Chesson HW. Treatment cost of acute gonococcal infections: Estimates from employer-sponsored private insurance claims data in the United States, 2003-2007. Sex Transm Dis 2010; 37:316-318.
17. Owusu-Edusei K, Doshi SR, Apt BS, et al. The direct cost of chlamydial infections: Estimates for the employer-sponsored privately insured population in the United States, 2003-2007. Sex Transm Dis 2010; 37:519-521.
18. Gift TL, Malotte CK, Ledsky R, et al. A cost-effectiveness analysis of interventions to increase repeat testing in patients treated for gonorrhea or chlamydia at public sexually transmitted disease clinics. Sex Transm Dis 2005; 32:542-549. (Pubitemid 41318840)
19. Blandford JM, Gift TL. Productivity losses attributable to untreated infection with Chlamydia trachomatis and to associated pelvic inflammatory disease in reproductive-age women. Sex Transm Dis 2004; 33:S117-S121. (Pubitemid 44454725)
20. Bureau of Labor Statistics. Employer Costs for Employee Compensation. Report on the Internet. Available at: http://www.blsgov/news.release/ecec.toc. htm. Accessed April 12, 2010.
21. Bureau of Labor Statistics. Consumer price index-all urban consumers. Database on the Internet. Available at: http://www. bls.gov/cpihome.htm. 2007. Accessed July 1, 2010.
22. Anonymous. Chlamydia. In: Stratton KR, Durch JS, Lawrence RS, eds. Vaccines for the 21st Century: A Tool for Decision Making. Washington, DC: National Academy Press; 1999:149-158.
23. Smith KJ, Tsevat J, Ness RB, et al. Quality of life utilities for pelvic inflammatory disease health states. Sex Transm Dis 2008; 35:307-311. (Pubitemid 351619537)
24. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985; 5:157-177. (Pubitemid 16130640)
25. Kotz S, van Dorp JR .The Triangular Distribution. Beyond Beta. Hackensack, NJ: World Scientific Publishing Co Pt Ltd, 2004:1-32.
26. Maciosek MV, Coffield AB, Edwards NM, et al. Priorities among effective clinical preventive services. Am J Prev Med 2006; 31:52-61.
27. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health 2007; 28:365-391. (Pubitemid 46833348)
28. Cook J, Jeuland M, Maskery B, et al. Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. J Policy Anal Manage 2009; 258:6-28.
29. Welte R, Postma M, Leidl R, et al. Costs and effects of chlamydial screening: Dynamic versus static modeling. Sex Transm Dis 2005; 32:474-483. (Pubitemid 41060386)
30. White PJ, Golden MR, Turner KME, et al. Patient-delivered partner therapy: When and where should it be used? Predicting its impact in the USA and UK. [Abstract] 2005. 16th Biennial Meeting of the International Society of Sexually Transmitted Disease Research; 10-13 July; Amsterdam, Netherlands.
31. Kretzschmar M, Turner KME, Barton PM, et al. Predicting the population impact of chlamydia screening programmes: Comparative mathematical modelling study. Sex Transm Infect 2009; 85:359-366.
32. Quinn TC, Gaydos CA, Shepherd M et al. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships. JAMA 1996; 276:1737-1742. (Pubitemid 26423966)
33. Rogers SM, Miller WC, Turner CF, et al. Concordance of Chlamydia trachomatis infections within sexual partnerships. Sex Transm Infect 2008; 84:23-28. (Pubitemid 351195846)
34. Washington AE, Johnson RE, Sanders LL Jr. Chlamydia trachomatis infections in the United States: What are they costing us? JAMA 1987; 257:2070-2072. (Pubitemid 17056751)
35. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: Insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100:456-463. (Pubitemid 35246131)
36. Douglas JM Jr, Newman D, Bolan G, et al. Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection [Abstract]. Int J STD AIDS 2001;12(suppl 2):65-67.
37. Low N, Sterne JAC, Harbord RM, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: The Uppsala women's cohort study. Sex Transm Infect 2006; 82:212-218. (Pubitemid 43901588)
38. Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: The POPI (prevention of pelvic infection) trial. Sex Transm Infect 2010; 340:c1642.
39. Smith KJ, Cook RL, Roberts MS. Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: Influence on the cost-effectiveness of different screening intervals. Value Health 2007; 10:358-366. (Pubitemid 47481107)
40. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: The case for screening. Prev Med 2003; 36:502-509. (Pubitemid 36315803)
41. Harrison William O, Hooper RR, Wiesner PJ, et al. A trial of minocycline given after exposure to prevent gonorrhea. N Engl J Med 1979; 300:1074-1078. (Pubitemid 9198741)